CVS Health has agreed to sell and issue about $4 billion in notes. The healthcare giant entered into an underwriting agreement with Barclays, J.P. Morgan Securities and Wells Fargo Securities on Aug.

Through the power of strategic, well-built partnerships, CVS Health helps employees earn degrees — and at no cost to them.

CVS Health topped Wall Street expectations for the second quarter and it's hiking its full-year forecast again, as the health care giant continued to rally under new management from a forgettable 2024 ...

CVS Health raised its full-year profit forecast after exceeding Wall Street quarterly earnings estimates on Thursday, as tight oversight of higher medical costs led to improved performance for its ...

CVS Health ( ($CVS) ) has shared an announcement. On August 11, 2025, CVS Health Corporation entered into an Underwriting ...

Fintel reports that on August 14, 2025, Baird upgraded their outlook for CVS Health (NYSE:CVS) from Neutral to Outperform.

CVS Health's troubles haven't been solely on the fundamental side. Indeed, shares have underperformed on the price charts, too, down 18% on a total return basis (price change plus dividends) so ...

It’s time for a wellness check at CVS Health. Shares of the company are down more than 20% this year as it grapples with higher-than-expected medical costs in its insurance unit and pharmacy ...

Creagh Milford, D.O., MPH, president of retail health for CVS, told Fierce Healthcare in an interview that while the national average wait time for a primary care visit is about 26 days, when he ...

CVS Health is coming off a tough quarter with multiple segments reporting lower earnings. It incurred $496 million in restructuring costs as a result of acquisitions and operations streamlining.

CVS announced that project earlier this year, and it involved a start-up company, Carbon Health. Through its acquisition of Oak Street Health, however, it could potentially go deeper into that.

CVS Health CVS 0.0% (NYSE: CVS) reported its Q3 results earlier this month, with revenues and earnings beating the street estimates, and we believe that CVS stock is undervalued, as discussed below.